tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

GSK Stock Latest News

Pfizer Stock (NYSE:PFE) – New FDA Approval Could Stop Its Drop
Market NewsPfizer Stock (NYSE:PFE) – New FDA Approval Could Stop Its Drop
4d ago
GSK
PFE
GSK Pharma call volume above normal and directionally bullish
The FlyGSK Pharma call volume above normal and directionally bullish
1M ago
GSK
Agenus up 4% after FDA approves GSK’s Arexvy RSV vaccine
The FlyAgenus up 4% after FDA approves GSK’s Arexvy RSV vaccine
1M ago
GSK
AGEN
GSK reports FDA approves Arexvy RSV vaccine for older adults
The FlyGSK reports FDA approves Arexvy RSV vaccine for older adults
1M ago
GSK
GSK reports Q1 adjusted EPS 37.0p vs 32.3p last year
The FlyGSK reports Q1 adjusted EPS 37.0p vs 32.3p last year
1M ago
GSK
GSK says EMA validates marketing authorization application for Jemperli
The FlyGSK says EMA validates marketing authorization application for Jemperli
1M ago
GSK
Bellus Health cut to Sector Perform at RBC Capital on GSK deal
The FlyBellus Health cut to Sector Perform at RBC Capital on GSK deal
2M ago
BLU
GSK
GSK to acquire Bellus Health for $14.75 per share
The FlyGSK to acquire Bellus Health for $14.75 per share
2M ago
BLU
GSK
Bellus Health Surges after Acquisition by GSK for $2 Billion
Market NewsBellus Health Surges after Acquisition by GSK for $2 Billion
2M ago
BLU
GSK
GSK reports EAGLE-2 and EAGLE-3 phase III trials met primary endpoint
The FlyGSK reports EAGLE-2 and EAGLE-3 phase III trials met primary endpoint
2M ago
GSK
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
The FlyReturn of Adaptimmune assets complements TCR pipeline, says Guggenheim
2M ago
GSK
ADAP
Adaptimmune taking back PRAME and NY-ESO target programs from GSK
The FlyAdaptimmune taking back PRAME and NY-ESO target programs from GSK
2M ago
GSK
ADAP
GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says
The FlyGSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says
2M ago
AZN
GSK
Scynexis price target raised to $9 from $8 at Guggenheim
The FlyScynexis price target raised to $9 from $8 at Guggenheim
2M ago
GSK
SCYX
Liquidia enters new, non-exclusive license agreement with GSK
The FlyLiquidia enters new, non-exclusive license agreement with GSK
2M ago
GSK
LQDA
‘Lots to like’ about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald
The Fly‘Lots to like’ about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald
2M ago
GSK
SCYX
GSK, PathAI collaborate on NASH Phase 2b clinical trial
The FlyGSK, PathAI collaborate on NASH Phase 2b clinical trial
2M ago
GSK
SCYNEXIS Skyrockets on Teaming Up With GSK for Fungal Treatment
Market NewsSCYNEXIS Skyrockets on Teaming Up With GSK for Fungal Treatment
2M ago
GSK
SCYX
Scynexis, GSK announce exclusive agreement to commercialize, develop Brexafemme
The FlyScynexis, GSK announce exclusive agreement to commercialize, develop Brexafemme
2M ago
GSK
SCYX
AnaptysBio ‘encouraged’ by GSK phase 3 trial results
The FlyAnaptysBio ‘encouraged’ by GSK phase 3 trial results
2M ago
GSK
ANAB
GSK says Phase III Ruby trial demonstrates Jemperli plus chemotherapy potential
The FlyGSK says Phase III Ruby trial demonstrates Jemperli plus chemotherapy potential
2M ago
GSK
GSK Pharma put volume heavy and directionally bearish
The FlyGSK Pharma put volume heavy and directionally bearish
2M ago
GSK